✦ LIBER ✦

272 EARLY VIRAL RESPONSE OF CONTROLLED-RELEASE INTERFERON ALPHA2B AND RIBAVIRIN VS. PEGYLATED-INTERFERON ALPHA2B AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE1 HEPATITIS C: 12 WEEK RESULTS (SELECT-2 TRIAL)

✍ Scribed by E. Lawitz; Z. Younossi; P. Mehra; A. Rigney; Z. Krastev; K. Tchernev; D. Takov; W.A. Long

Book ID: 117378358
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 50 KB
Volume: 52
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(10)60274-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

444 SVR FOR CONTROLLED-RELEASE INTERFERO

444 SVR FOR CONTROLLED-RELEASE INTERFERON ALPHA-2B (CR2B) +RIBAVIRIN COMPARED TO PEGYLATED INTERFERON ALPHA-2B (PEG2B) +RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 (G1) HEPATITIS C: FINAL RESULTS FROM SELECT-2

✍ E. Lawitz; Z. Younossi; R. Mehra; A. Rigney; Z. Krastev; K. Tchernev; D. Takov; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 116 KB

58 RANDOMIZED, OPEN-LABEL, 12-WEEK COMPA

58 RANDOMIZED, OPEN-LABEL, 12-WEEK COMPARISON OF CONTROLLED-RELEASE INTERFERON ALPHA2B +RIBAVRIN VS. PEGYLATED-INTERFERON ALPHA2B +RIBAVRIN IN TREATMENT-NAIVE GENOTYPE1 HEPATITIS C: 4 WEEK RESULTS FROM 480STUDY (PANEL A)

✍ Z. Krastev; I. Kotzev; K. Tchernev; A. Rigney; D. Nikolovska; B. Vladimirov; F.A 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 93 KB

Preliminary treatment results of pegylat

Preliminary treatment results of pegylated interferon alpha 2B and ribavirin in liver transplant recipients with recurrent hepatitis C virus nonresponsive to interferon alpha2B and ribavirin

✍ G.W. Neff; M. Montalbano; N. Ozden; H. Muslu; Y.M. Lee; K. Safdar; R. Morrero; J 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 161 KB

Short treatment (14 weeks) with pegylate

Short treatment (14 weeks) with pegylated interferon alpha-2B and ribavirin for the treatment of hepatitis C genotype 2/3 infection

✍ O. Dalgard; K. Skaug; S. Ritland; B. Myrvang; K. Hellum; K. Bjoro; H. Bell 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 307 KB

Pegylated interferon alpha-2b plus ribav

Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response

✍ Sanaa M. Kamal; Samer S. El Kamary; Michelle D. Shardell; Mohamed Hashem; Imad N 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 251 KB 👁 2 views

In patients chronically infected with hepatitis C virus (HCV) genotype 4, the optimum duration of therapy and the predictors of sustained virologic response (SVR) have not been adequately determined. In this study, 358 patients with chronic hepatitis C genotype 4 were randomly assigned to pegylated

733 Interim (week 12) phase 2b virologic

733 Interim (week 12) phase 2b virological efficacy and safety results of albumin interferon Alpha-2b combined with ribavirin in genotype 1 chronic hepatitis C infection

✍ S. Zeuzem; Y. Benhamou; D. Shouval; V. Bain; S. Pianko; R. Flisiak; M. Grigoresc 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 114 KB